THANK YOU FOR SUBSCRIBING
NodThera, for discovery of (NLRP3 ) inflammasome inhibitors to treat diseases caused by chronic inflammation, closed a $40M Series A financing round.
The second closing round was co-led by 5AM Ventures and Sofinnova Partners, with advance investment from F-Prime Capital Partners & Epidarex Capital. Along with the funding, Managing partner of Sofinnova Partners, Henrijette Richter, PhD, and Scott Rocklage, PhD, Founding Partner of 5AM Ventures, serve the chair by joining the Board of Directors with Henrijette Richter.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Epidarex Capital, life science investor and seed funder in 2016 in light of prior research directed at Selvita, a medication disclosure firm located in poland which remains a shareholder in the organization, NodThera aim is to develop and discover cutting-edge NLRP3 inflammasome inhibitors for the treatment of sicknesses driven by chronic inflammation.
Led by Alan Watt Ph.D. MBA, Chief Scientific Officer, and acting Chief Executive Officer, the organization is developing small molecule inhibitors of the NLRP3 inflammasome, a multi-protein complex which starts an innate immune reaction in the body. The NodThera technique is to build up its medication hopeful through to evidence of-idea in people in an incendiary ailment and to present further medication applicants particularly tending to high unmet medical needs, for example, neurodegenerative diseases and certain cancers.
Check Out Review Of CIOReview : Crunchbase, Glassdoor
Check This Out : CIOReview Overview, Muckrack
More in News